Hologic Company Profile (NASDAQ:HOLX)

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic, Inc. (NASDAQ:HOLX) posted its quarterly earnings results on Wednesday, May, 10th. The company reported $0.50 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.46 by $0.04. The business earned $715.40 million during the quarter, compared to the consensus estimate of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The company's quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.47 earnings per share. View Hologic's Earnings History.

Hologic issued an update on its FY17 earnings guidance on Wednesday, May, 10th. The company provided earnings per share guidance of $1.98-2.02 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.98. The company issued revenue guidance of $3.05-3.08 billion, compared to the consensus revenue estimate of $3.06 billion.Hologic also updated its Q3 guidance to $0.48-0.50 EPS.

13 brokerages have issued 12 month price objectives for Hologic's stock. Their predictions range from $39.00 to $53.00. On average, they expect Hologic's stock price to reach $47.69 in the next twelve months. View Analyst Ratings for Hologic.

Here are some recent quotes from research analysts about Hologic stock:

• 1. According to Zacks Investment Research, "Hologic witnessed a lackluster performance at its Diagnostics segment in the last reported quarter. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, the company has been registering strong top line growth in recent times driven by strength in molecular diagnostics, GYN Surgical and Breast Health businesses. The company's raised guidance for fiscal 2017 indicates that this growth momentum should continie through rest of the year.  In fact, the recent European approval for the company's new Panther system should boost growth in the coming quarter. For the last three months, Hologic has been trading above the broader Medical Instruments industry in terms of price. Hologic’s strong cash position is another encouraging factor." (7/12/2017)
• 2. Needham & Company LLC analysts commented, "HOLX is acquiring Cynosure (CYNO) for $1.44B with an all-cash tender offer. CYNO is a leading aesthetics company that competes in a $2B market growing in the double-digits with a range of products used for hair removal, body contouring, skin revitalization, and other cosmetic procedures. HOLX expects CYNO to increase its revenue growth and add $0.13-0.15 to its FY18E EPS. HOLX has now effectively swapped a business with declining sales and margins (blood screening) for one with double-digit growth and improving margins (CYNO). With the blood screening EPS "hole" now partially filled and HOLX facing increasingly easy comps over the next three quarters, we upgrade to Buy." (2/15/2017)

Some companies that are related to Hologic include Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), GenMark Diagnostics (GNMK) and LeMaitre Vascular (LMAT).

Hologic's management team includes the folowing people:

• Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
• Robert W. McMahon, Chief Financial Officer
• Sanjay Prabhakaran, Regional President - Asia
• Peter J. Valenti III, Division President- Breast and Skeletal Health
• Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
• Thomas A. West, Division President- Diagnostics
• Eric B. Compton, Chief Operating Officer
• Michael J. Watts, Vice President, IR Contact Officer
• John M. Griffin, General Counsel
• Elaine S. Ullian, Lead Independent Director

Hologic's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (1.22%), Russell Investments Group Ltd. (0.38%), Ardevora Asset Management LLP (0.28%), First Quadrant L P CA (0.23%), Gateway Investment Advisers LLC (0.18%) and GW&K Investment Management LLC (0.14%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III, Sally Crawford and Wayne Wilson. View Institutional Ownership Trends for Hologic.

Hologic's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Nisa Investment Advisors LLC, Creative Planning, Exxonmobil Investment Management Inc. TX, Chemung Canal Trust Co., Hartford Investment Management Co., Webster Bank N. A. and Capstone Asset Management Co.. Company insiders that have sold Hologic stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Hologic's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bank of Montreal Can, Greenleaf Trust, First Quadrant L P CA, GW&K Investment Management LLC, Ardevora Asset Management LLP, Mn Services Vermogensbeheer B.V. and Acadian Asset Management LLC. View Insider Buying and Selling for Hologic.

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Hologic stock can currently be purchased for approximately $45.09.